Trials / Completed
CompletedNCT06709820
A Study of LY4060874 in Healthy Participants
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4060874 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 121 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants. Study participation may last up to 22 weeks and up to approximately 18 study visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY4060874 | Administered SC |
| DRUG | LY4060874 | Administered IV |
| DRUG | Placebo | Administered SC |
| DRUG | Placebo | Administered IV |
Timeline
- Start date
- 2024-12-02
- Primary completion
- 2026-02-20
- Completion
- 2026-02-20
- First posted
- 2024-11-29
- Last updated
- 2026-04-03
Locations
2 sites across 2 countries: United States, Singapore
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06709820. Inclusion in this directory is not an endorsement.